News

With more than 80 years of history, the laboratory founded in Barcelona continues to advance its sustainable growth strategy through alliances with leading international partners Laboratorios ERN is taking a decisive step in strengthening its respiratory portfolio with the launch in Spain of Luforbec® (beclometasone / formoterol), 100/6, a fixed-dose...

Laboratorios ERN and Ercros are beneficiaries of public funding awarded under the National Cooperative R&D Programme of the Centre for the Development of Technology and Innovation (CDTI) Thanks to this funding, both companies are jointly advancing the ANTISALINA project, aimed at developing new innovative solutions in the field of research and...

The commercialization of intravenous fosfomycin has begun in the United States This hospital-use antibiotic is a key treatment for complicated urinary tract infections and is being introduced through a strategic agreement between LABORATORIOS ERN and the pharmaceutical company Meitheal Pharmaceuticals, a specialist in the commercialization of generic and...

We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the...

During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health,...

From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level speakers The...

David Solanes López, General Manager of Laboratorios ERN, was appointed Academician of the Royal Academy of Pharmacy of Catalonia on October 6, 2025, in the industrial section Solanes dedicated his induction speech to incremental innovation, an area closely linked to his professional career and to Laboratorios ERN’s commitment to developing solutions...

On October 22, 2025, the US Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI) Laboratorios ERN expresses its satisfaction with the recent approval by the US Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older...

The collaboration with the Institut de Formació Contínua–IL3 allows students to apply their knowledge to a real case in the pharmaceutical sector Laboratorios ERN has strengthened its ties with the academic field through a collaboration with the Master’s in Logistics and Supply Chain Management at the Institut de Formació Contínua–IL3, part of...